Zhuzhou Qianjin Pharmaceutical Co., Ltd.

Zhuzhou Qianjin Pharmaceutical Co., Ltd. has recently experienced an evaluation adjustment, reflecting its flat financial performance and market position. The company reported minimal growth in net sales and operating profit, alongside concerns regarding operating cash flow and return on capital employed, indicating challenges for long-term growth.

Zhuzhou Qianjin Pharmaceutical Co., Ltd. has undergone a recent evaluation adjustment, reflecting a more favorable view of its financial health. Key metrics, including a competitive P/E ratio and a dividend yield of 3.70%, indicate a solid market position, despite modest long-term growth in sales and profits.

Zhuzhou Qianjin Pharmaceutical Co., Ltd. has experienced a recent evaluation adjustment, reflecting a shift in its stock valuation metrics. Key financial indicators include a P/E ratio of 19 and a price-to-book value of 1.78, while the company faces challenges in long-term growth and has underperformed the market.

Zhuzhou Qianjin Pharmaceutical Co., Ltd. saw a notable decline in its stock today, contrasting with the broader market's performance. Over the past week and month, the stock has experienced significant decreases, while year-to-date figures show it underperforming compared to the market. Financial metrics reveal slow growth in net sales and operating profit.